These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 25140014)

  • 1. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neprilysin inhibition and chronic kidney disease].
    Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
    G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Judge PK; Haynes R
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):123-130. PubMed ID: 33148948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
    Tummala R; Bhadra R; Gupta A; Ghosh RK
    J Cardiovasc Pharmacol; 2016 Sep; 68(3):183-90. PubMed ID: 27092662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?
    Malek V; Gaikwad AB
    Biomed Pharmacother; 2017 Jun; 90():752-759. PubMed ID: 28419972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
    Buggey J; Mentz RJ; DeVore AD; Velazquez EJ
    J Card Fail; 2015 Sep; 21(9):741-50. PubMed ID: 26209000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Vilela-Martin JF
    Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
    Packer M; McMurray JJ; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Bělohlávek J; Böhm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzàlez-Medina A; Hagège AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan Ö; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJ; Refsgaard J; Rosenthal A; Senni M; Sibulo AS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RC;
    Circulation; 2015 Jan; 131(1):54-61. PubMed ID: 25403646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LCZ696 : a new paradigm for the treatment of heart failure?
    Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
    Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiotensin-neprilysin inhibition in ckd: does it confer a double benefit?].
    Wojtaszek E
    Wiad Lek; 2019; 72(11 cz 2):2228-2231. PubMed ID: 31860842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
    Singh JS; Lang CC
    Vasc Health Risk Manag; 2015; 11():283-95. PubMed ID: 26082640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.